All Stories

Pfizer outlines Talzenna's survival benefit in bid for broad prostate cancer approval

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug's already broadest-in-class U.S. label in prostate cancer.

Feb 13, 2025 - 16:04
 0
Pfizer outlines Talzenna's survival benefit in bid for broad prostate cancer approval
Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug's already broadest-in-class U.S. label in prostate cancer.
Read More

Tags:

Previous Article

VinFast announces 4Q24 global deliveries, January 2025 domestic deliveries

Next Article

Reform MP installed solar to cut bills but party calls renewables ‘massive con’

Related Posts

Regulatory tracker: China approves its first gene therapy

Regulatory tracker: China approves its first gene therapy

Apr 10, 2025  0

Few psych drugs from past decade are on HCPs’ radars: survey

Few psych drugs from past decade are on HCPs’ radars: s...

Apr 10, 2025  0

With Eli Lilly flying high, CEO David Ricks collects 10% pay bump to $29.2M

With Eli Lilly flying high, CEO David Ricks collects 10...

Mar 10, 2025  0